Literature DB >> 29305014

NF-κB and the Transcriptional Control of Inflammation.

Jennifer P Mitchell1, Ruaidhrí J Carmody2.   

Abstract

The NF-κB transcription factor was discovered 30 years ago and has since emerged as the master regulator of inflammation and immune homeostasis. It achieves this status by means of the large number of important pro- and antiinflammatory factors under its transcriptional control. NF-κB has a central role in inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and autoimmunity, as well as diseases comprising a significant inflammatory component such as cancer and atherosclerosis. Here, we provide an overview of the studies that form the basis of our understanding of the role of NF-κB subunits and their regulators in controlling inflammation. We also describe the emerging importance of posttranslational modifications of NF-κB in the regulation of inflammation, and highlight the future challenges faced by researchers who aim to target NF-κB transcriptional activity for therapeutic benefit in treating chronic inflammatory diseases.
© 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Cancer; Inflammation; NF-κB; Regulation; Toll-like receptor tolerance; Transcription

Mesh:

Substances:

Year:  2017        PMID: 29305014     DOI: 10.1016/bs.ircmb.2017.07.007

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  94 in total

1.  Differential regulation of basal expression of inflammatory genes by NF-κB family subunits.

Authors:  Tristan J de Jesús; Joshua T Centore; Parameswaran Ramakrishnan
Journal:  Cell Mol Immunol       Date:  2019-05-29       Impact factor: 11.530

Review 2.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

3.  The Role of NF-κB/NLRP3 Inflammasome Signaling Pathway in Attenuating Pyroptosis by Melatonin Upon Spinal Nerve Ligation Models.

Authors:  Yi-Hao Wang; Xiao Gao; Yu-Ru Tang; Yang Yu; Ming-Jie Sun; Fu-Qiang Chen; Yan Li
Journal:  Neurochem Res       Date:  2021-09-13       Impact factor: 3.996

Review 4.  Emerging role of protein modification in inflammatory bowel disease.

Authors:  Gaoying Wang; Jintao Yuan; Ji Luo; Dickson Kofi Wiredu Ocansey; Xu Zhang; Hui Qian; Wenrong Xu; Fei Mao
Journal:  J Zhejiang Univ Sci B       Date:  2022-03-15       Impact factor: 3.066

Review 5.  Spinal Microglia and Astrocytes: Two Key Players in Chronic Visceral Pain Pathogenesis.

Authors:  Jun-Yi Long; Xue-Jun Wang; Xiao-Ying Li; Xie-He Kong; Guang Yang; Dan Zhang; Yan-Ting Yang; Zheng Shi; Xiao-Peng Ma
Journal:  Neurochem Res       Date:  2021-11-19       Impact factor: 3.996

6.  Inhibitory feedback control of NF-κB signalling in health and disease.

Authors:  Jack A Prescott; Jennifer P Mitchell; Simon J Cook
Journal:  Biochem J       Date:  2021-07-16       Impact factor: 3.857

Review 7.  Isoflavones and inflammatory bowel disease.

Authors:  Ze-Yu Wu; Li-Xuan Sang; Bing Chang
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

Review 8.  Immunomodulation by anticancer cell cycle inhibitors.

Authors:  Giulia Petroni; Silvia C Formenti; Selina Chen-Kiang; Lorenzo Galluzzi
Journal:  Nat Rev Immunol       Date:  2020-04-28       Impact factor: 53.106

9.  Association between NF-kB polymorphism and age-related macular degeneration in a high-altitude population.

Authors:  Yan Xin; Kang Zefeng; Li Ling; Guan Ruijuan
Journal:  PLoS One       Date:  2021-06-08       Impact factor: 3.752

Review 10.  The Role of Chinese Herbal Therapy in Methamphetamine Abuse and its Induced Psychiatric Symptoms.

Authors:  Lin Chen; Qin Ru; Qi Xiong; Mei Zhou; Kai Yue; Yuxiang Wu
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.